Bayer's sales fall 4% in Spain, to 787 million

BarcelonaThe pharmaceutical company Bayer billed 787 million euros in 2025 in Spain. The figure represents a drop of 4% compared to the previous year, in which the firm achieved sales of 822 million. As explained by the CEO of the Bayer subsidiary in Spain, Jordi Sánchez, the drop in billing is mainly due to the withdrawal from the market of the insecticide Movento, which has been banned in Europe. This impact has been particularly noticeable in the sales of the company's agricultural division –the Crop Science area–, which has reduced sales by 20%, to 227 million euros.

"Last year was a year of adaptation," explained the director of the area focused on agriculture, Pierre Larrieu. Larrieu specified that they are currently working to launch a package of solutions so that farmers can replace the banned insecticide, as, as he explained, there is no single product that can replace it. Without considering the effect of the ban, the director of the agricultural division explained that the business would have experienced a growth of 5%. Movento was withdrawn from the European market for public health and environmental reasons. However, the executive pointed out that it is "safe" and that, for this reason, it continues to be marketed outside of Europe.

"An exceptional year"

However, the other two divisions of the multinational have experienced sales growth. Specifically, the pharmaceutical area increased its turnover by 2%, to 418 million euros, and consolidated itself as the company's main activity in Spanish territory. During 2025, sales of self-care products – from the Consumer Health division – reached 142 million euros, representing a growth of 13% compared to 2024. "It has been an exceptional year," valued the director of the area, Marielle López, who explained that they foresee three new launches for 2026.

Regarding investments, the CEO of the company based in Sant Joan Despí highlighted that during the past year they maintained an investment of 145 million euros in Spain, the majority of which (120 million) focused on research and development projects. The remaining 25 million were used for the development of the 11 centers that Bayer has throughout Spanish territory. For 2026, the company has not defined an investment objective, just as they have not yet estimated what economic consequences they may experience due to the war in Iran. However, Sánchez stated that they have contingency plans to cope with logistical and energy impacts.